Recruiting
Phase 2

Metformin

Sponsor:

UCLA

Code:

NCT07693452

Conditions

Appendiceal Mucinous Neoplasm

Pseudomyxoma Peritonei

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Metformin

Study Details

Brief summary:

This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritonei (PMP) secondary to appendiceal mucinous neoplasms (AMNs).

Conditions

Appendiceal Mucinous Neoplasm

Pseudomyxoma Peritonei

Study ID

NCT07693452

Start date

Jun 18, 2026

Status verified date

Jul, 2026

Completion date

Jul, 2029

Anticipated

Primary completion date

Feb, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Key Inclusion Criteria (complete details available in protocol):

  • Patients with clinical diagnosis of pseudomyxoma peritonei (PMP) secondary to presumed appendiceal mucinous neoplasms (AMNs) with recurrent/refractory disease s/p cytoreductive surgery(CRS)/hyperthermic intraperitoneal chemotherapy (HIPEC), unresectable disease, or without planned CRS/HIPEC
  • Age ≥18 years
  • ECOG performance status ≤2

Key Exclusion Criteria (complete details available in protocol):

  • Patients with a clinical diagnosis of PMP secondary to presumed AMNs with resectable disease who are planned to undergo CRS/HIPEC
  • Patients currently taking metformin for another medical indication
  • Patients with a prior adverse event to administration of metformin

Study Design

Enrollment

15 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Metformin Treatment

850mg PO daily

Interventions

Metformin

Given PO

Primary outcome measure

  • Proportion of Participants who have completed at least (≥) 80% of planned metformin doses by 6 months [ Time Frame: 6 months ]

Central Contacts and Locations

Central contacts

Chao Family Comprehensive Cancer Center University of California, Irvine

1-877-827-8839ucstudy@uci.edu

Locations

Chao Family Comprehensive Cancer Center, University of California, Irvine

Recruiting

Orange, California, United States, 92868

Contacts

Oliver Eng, MD

877-827-8839ucstudy@uci.edu

More Information

Sponsor

University of California, Irvine

Last update posted

Jul 13, 2026

Last verified

Jul, 2026

Keywords

  • Appendiceal Mucinous Neoplasm
  • Pseudomyxoma Peritonei
  • Pseudomyxoma Peritoneal
  • PMP
  • AMNs
  • Metformin

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, Irvine on 2026-07-13.